ArticleDiscover oncology2026
Mechanistic investigation of artesunate against head and neck squamous cell carcinoma through network pharmacology and experimental validation.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundArtesunate (ART), a semisynthetic derivative of artemisinin, has demonstrated antitumor activity in multiple malignancies; however, its cytotoxic activity and underlying mechanisms in head and neck squamous cell carcinoma (HNSCC) remain incompletely understood.
methodsNetwork pharmacology and molecular docking were employed to predict potential molecular targets of ART in HNSCC. The effects of ART on cell viability, migration, invasion, and apoptosis were evaluated in SCC-25 and CAL27 cells in vitro. Expression changes in the Bcl-2/Bax/Caspase-3 axis were assessed using Western blotting and RT-qPCR. A xenograft model was further established to examine the in vivo antitumor activity of ART.
resultsNetwork pharmacology analysis identified 77 potential ART-associated targets related to HNSCC. GO and KEGG enrichment analyses suggested that these targets were involved in several cancer-related pathways. PPI analysis highlighted six core targets, among which CASP3 exhibited the most favorable predicted interaction with ART in docking analysis. Experimental results showed that ART treatment was associated with reduced cell viability, migration, and invasion, along with increased apoptotic activity in HNSCC cells. These effects were accompanied by an increased Bax/Bcl-2 ratio and elevated cleaved Caspase-3 levels. In the xenograft model, ART treatment suppressed tumor growth and increased tumor cell apoptosis.
conclusionART demonstrates preclinical antitumor activity in HNSCC and is associated with activation of Bcl-2/Bax/Caspase-3 axis. These findings provide preliminary mechanistic insight and support further investigation of ART in preclinical models of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.